Adva Biotechnology And Autolomous Announce Collaboration To Co-Lead The Digital Pioneer Program For Scalable Autologous Cell Therapy Manufacturing

Adva Biotechnology Ltd. and Autolomous Ltd. have announced a strategic collaboration to co-lead the Digital Pioneer Program, an early adopter initiative focused on digitising, decentralising, and scaling out autologous cell therapy manufacturing.

The program brings together Adva’s automated and closed-system manufacturing platform with Autolomous’ advanced digital orchestration and manufacturing management technologies, forming an integrated solution designed to assure right-first-time production processes are developed, with full data traceability and compliance, in order to reduce overall time-to-patient of life-saving therapies.

“Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model,” said Dr. Ohad Karnieli, Founder and CEO of Adva Biotechnology. “This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one.”

By joining the Digital Pioneer Program, visionary forerunners will be able to evaluate, pilot, and clinically translate this next-generation manufacturing model.

“Our mission is simple: to bring life-saving therapies to all patients around the world, safer, faster, and affordable. By providing a digital-first infrastructure to the industry, we are removing the barriers between innovation and the patient,” said Alexander Seyf, Co-Founder and CEO of Autolomous. “This program is a call to action, offering a foundation that will help us build the future of personalised medicine – one defined by trust, equity, and most importantly, acting for hope.”

The Digital Pioneer Program is now open for inquiries from cell therapy developers interested in adopting next-generation manufacturing technologies. Adva and Autolomous are wholeheartedly welcoming committed innovators from across the globe to join our mission.

About Adva Biotechnology
Adva Biotechnology is at the forefront of revolutionizing cell therapy manufacturing. By providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies. Their flagship product, the ADVA X3 platform, is a fully controlled, smart, flexible, and automated cell processing system. It leverages the unique CAMP(R)(Continuous Adaptive Multi-Parameter) technology, which streamlines autologous cell therapy manufacturing processes. Through automation, metabolic sensing, and artificial intelligence, Adva Biotechnology aims to remove the manual component from the process, ultimately advancing treatments for various forms of cancer and other conditions. Their commitment to improving patient outcomes through innovative technology underscores their mission: valuing life, granting advanced therapies to patients. For more information, visit www.advabio.com.

About Autolomous
Autolomous is a leading software provider for cell and gene therapy manufacturing. Their flagship product, autoloMATE, offers a comprehensive suite of features for electronic batch records, data management, orchestration, and quality release, ensuring cGMP compliance and facilitating efficient production of life-saving therapies. Rooted in London (UK) and recently expanded into New York (USA), Autolomous was brought to life in 2019 by a team of seasoned professionals whose expertise spans advanced therapies, medical practice, and enterprise-level technology, software, and business. For more information, visit www.autolomous.com.